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Abstract
Nalbuphine, an agonist-antagonist kappa-opioid, produces brief analgesia followed by enhanced pain/hyperalgesia in male
postsurgical patients. However, it produces profound analgesia without pain enhancement when co-administration with
low dose naloxone. To examine the effect of nalbuphine or nalbuphine plus naloxone on activity in brain regions that may
explain these differences, we employed pharmacological magnetic resonance imaging (phMRI) in a double blind cross-over
study with 13 healthy male volunteers. In separate imaging sessions subjects were administered nalbuphine (5 mg/70 kg)
preceded by either saline (Sal-Nalb) or naloxone 0.4 mg (Nalox-Nalb). Blood oxygen level-dependent (BOLD) activation
maps followed by contrast and connectivity analyses revealed marked differences. Sal-Nalb produced significantly increased
activity in 60 brain regions and decreased activity in 9; in contrast, Nalox-Nalb activated only 14 regions and deactivated
only 3. Nalbuphine, like morphine in a previous study, attenuated activity in the inferior orbital cortex, and, like noxious
stimulation, increased activity in temporal cortex, insula, pulvinar, caudate, and pons. Co-administration/pretreatment of
naloxone selectively blocked activity in pulvinar, pons and posterior insula. Nalbuphine induced functional connectivity
between caudate and regions in the frontal, occipital, temporal, insular, middle cingulate cortices, and putamen; naloxone
co-admistration reduced all connectivity to non-significant levels, and, like phMRI measures of morphine, increased
activation in other areas (e.g., putamen). Naloxone pretreatment to nalbuphine produced changes in brain activity possess
characteristics of both analgesia and algesia; naloxone selectively blocks activity in areas associated with algesia. Given
these findings, we suggest that nalbuphine interacts with a pain salience system, which can modulate perceived pain
intensity.
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Introduction
In clinical studies of the analgesic efficacy of agonist-antagonist
kappa opioids we found that all three clinically available agents in
this class (viz., nalbuphine, pentazocine, and butorphanol) produce
sexually dimorphic analgesia [1,2], with males experiencing
significantly less analgesia than females. Although the reasons for
this sex difference have not been determined, a placebo-controlled
dose response study of the analgesic effect of nalbuphine in
patients experiencing moderate to severe post-operative pain
showed that males, and not females, receiving the lowest dose of
nalbuphine (5 mg), reported significantly greater pain than those
receiving placebo [3], suggesting the presence of a pain-facilitating
mechanism in males, not present or significantly diminished in
females. Subsequently, we found that co-administration of the
opioid antagonist naloxone, at low dose, abolished pain facilitation
in males, resulting in profound analgesia that was very similar to
that produced by nalbuphine in females [4]. Based on these
findings we hypothesized that nalbuphine has pain-facilitating as
well as analgesic effects produced by action at different receptors
in the brain, an ‘‘analgesia’’ receptor, likely the k-opioid receptor
[5] and a ‘‘pain-facilitating’’ receptor, and that the latter, which is
predominantly found in males, is more sensitive to naloxone. This
model could explain the ability of naloxone to enhance analgesia
by selectively blocking the pain-facilitating effect of nalbuphine.
The present study investigated putative analgesia and pain-
facilitation brain circuitry affected by nalbuphine, in males. Since
a radio-ligand for k-opioid receptors is not currently available for
use in human positron emission tomography (PET) or single
positron emission tomography (SPECT) studies, we employed
pharmacological magnetic resonance imaging (phMRI), a form of
functional magnetic resonance imaging (fMRI), to identify regions
of the brain whose blood oxygen level-dependent (BOLD) signals
are increased or decreased by nalbuphine in subjects pretreated
with either saline or naloxone. Important to the present study,
phMRI (a measure of BOLD activation/brain function as a direct
consequence of drug induced activity) is a technique that enables
PLOS ONE | www.plosone.org 1 January 2013 | Volume 8 | Issue 1 | e50169the measures of activity in brain regions affected by analgesics and
other drugs without sensory stimulation [6,7]. We have previously
used phMRI to study other opioid agonists and antagonists
including morphine [8] and naloxone [9], and most recently
buprenorphine [10], demonstrating the utility of this approach to
evaluate drug action on brain circuits.
In the present study male volunteers were administered
nalbuphine preceded by vehicle saline or nalbuphine preceded
by naloxone, in a double blind, crossover, two-session design to
test the hypothesis that nalbuphine affects activity in brain regions
and circuits related to pain-facilitation, as well as analgesia, and its
effects on sites and circuits involved in possible pain facilitation are
attenuated by naloxone pretreatment/co-administration.
Methods
To investigate the differences in phMRI brain activation
produced by nalbuphine and nalbuphine in combination with
naloxone, each subject was scanned twice in a cross-over double
blind study. Thus, each subject received nalbuphine infusions on
each trial, once with saline pretreatment (Sal-Nalb) and once with
naloxone pretreatment (Nalox-Nalb).
Subjects
Recruitment. The McLean Hospital Institutional Review
Board approved the study. The study also complied with the
guidelines of the Helsinki Accord and International Association for
the Study of Pain (IASP) for experimental pain research in
humans. Fifteen healthy male volunteers (age 24.0762.56 (mean
6 SD)) were recruited through advertisements in local newspa-
pers, flyers on local college campuses, and on recruiting websites
(Partners research site (CRNet), and Craig’s List (http://boston.
craigslist.org/). All subjects signed a written informed consent to
participate in the study.
Enrollment. Healthy right-handed male candidates 18–45
years of age attended a screening session where compliance with
inclusion/exclusion criteria was evaluated and a full medical
examination including was performed by a board certified
neurologist. Inclusionary criteria. Candidates meeting any of the
following criteria were excluded from participation in the study:
current use of prescribed medications, BDI score .11, history of
opioid abuse, history of smoking within the past year, claustro-
phobia, significant medical problems, significant alcohol intake
(five or more glasses/week), history of allergy or untoward reaction
to anticonvulsants, metal implants of any type, weight greater than
130 kg. An FDA-approved urine toxicology screen (7 Drug
InstaStrip Drug Screen Test, Cortez Diagnostics, Calabasas,
CA), which tested for barbiturates, benzodiazepines, amphet-
amine, cocaine, tetrahydrocannabinol, phencyclidine and opioids,
was performed prior to each MR session. None of the subjects had
a positive drug screen. Thirteen of the 15 subjects (three Asian,
one black, 9 white, aged 2462.56 years (mean 6 s.d), weight
79616.4 kg, completed both scanning sessions.
Subject Preparation. All subjects were instructed to refrain
from eating starting eight hours before the scan but were allowed
to consume clear liquids. Subjects were scheduled for their second
scan two weeks after the first.
Study Design
Drug Administration. Naloxone and nalbuphine (both from
Hospira Inc., Lake Forest, IL) were administered through
contralateral intravenous lines placed in the antecubital region of
each arm. Naloxone (0.4 mg) or saline was followed 5, 7, 9 and
11 minutes later by a divided dose of nalbuphine (5 mg/70 kg)
administered through the access port in the left arm in 2 ml
boluses at 0.1 ml/s (Fig. 1). Doses were chosen on the basis of our
previous clinical studies [3,4,11]. Nalbuphine administration was
carried out with an MRI-compatible microinjector (Medrad
Spectris, Colombus, OH).
Randomization. To neutralize any effect of treatment order,
about half of the subjects received saline first and the other half
received naloxone first, in a randomized, double-blinded, cross-
over design. Subjects as well as team members involved in drug
administration and initial analysis were blinded to drug group
assignment.
Scanning
Anatomical scans were acquired prior to drug administration
(Fig. 1). Infusion scanning began immediately after infusion of
naloxone or saline (five minutes before infusion of the first bolus of
nalbuphine).
Data Acquisition. Data were collected on a 3T Siemens Trio
scanner with an 8-channel phased array head coil (Erlangen,
Germany). phMRI data were collected using a gradient echo-echo
planar pulse sequence (GE-EPI) at 3.563.563.5 mm
3 resolution.
GE-EPI Parameters. Time of Repetition (TR)=2500 msec,
Time of Echo (TE)=30 msec, Field of View (FOV)=2246224,
Flip Angle (FA)=90u, number of Slices=41 axial slices and
number of Volumes=600. The acquisition time for the infusion
scan was 25 min 5 sec. T1-weighted structural images were
acquired using a 3-D magnetization-prepared rapid gradient echo
(MPRAGE) sequence at a resolution of 1.3361.061.0 mm
3.
MPRAGE Parameters: TR=2100 msec, TE=2.74 msec, Time
of Inversion (TI)=1100 msec, FA=12u, number of Slices=128
sagittal slices.
Ancillary Measures
Hedonic Ratings. Hedonic ratings were recorded following
nalbuphine administration. Prior to the scan subjects were
instructed on how to rate their hedonic experiences using a dial
controlled by the right hand and a visual analog scale (VAS)
display that could be seen from within the bore of the magnet. The
VAS anchors were ‘neutral’ in the middle of the scale, ‘max
euphoria’ on the right, and ‘max dysphoria’ on the left.
Physiological Measures. Throughout the period of the
scans, pulse oximetry was employed to monitor heart rate (HR)
and blood oxygen saturation (SpO2), and a nasal cannula was
placed to monitor respiratory rate (RR) and end tidal CO2.
Imaging Data Analysis
Preprocessing. Anatomical data: High resolution anatomical
images for each subject were bias-corrected and segmented into
white matter (WM), gray matter (GM) and cerebrospinal fluid
(CSF) using FAST [12].
phMRI data: Preprocessing was performed using tools from the
FMRIB Software Library (FSL) (http://www.fmrib.ox.ac.uk/fsl/).
The first 2 volumes were removed from each subject’s phMRI
dataset to allow the MR signal to stabilize.
Preprocessing steps on the remaining 4D volume included: (1)
motion-correction using MCFLIRT [13]; (2) brain extraction
using BET [14]; (3) spatial smoothing using an isotropic Gaussian
kernel of 5 mm FWHM; (4) grand mean intensity normalization of
the entire 4D dataset by a single multiplicative factor; (5)
registration of the functional space template to the anatomical
space and the MNI 152 space using an affine transform with 12
degrees of freedom via FLIRT [13]; and (6) creation of the WM
and CSF masks in functional space for each subject using the
functional space affine transformation.
Pharmacological MRI (phMRI) of Nalbuphine
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interest is a low frequency infusion response. Preprocessed phMRI
was inspected for scanner artifacts using a linear independent
component analysis (ICA) based approach [15]. Confounding
artifacts were removed from the phMRI before statistical analysis.
Infusion analysis
Single subject. Analysis was performed using a generalized
linear model (GLM) with Gaussian noise. The ideal infusion
response (infusion EV) was modeled as a ramped unit step function
with a 5 min baseline, a ramp going from 5 min to 13 min and a
plateau thereafter. The infusion EV was not convoluted to a
hemodynamic response function. The key statistic of interest is the
Figure 1. Drug administration protocol. After the initial anatomical scans were obtained, either naloxone or saline was infused for Scan 1; for
Scan 2 the other drug was infused. Nalbuphine infusion was then started five minutes later. One quarter of the nalbuphine dose was administered
every other minute until the full amount was delivered by eight minutes.
doi:10.1371/journal.pone.0050169.g001
Figure 2. Examples of infusion-initiated BOLD signal changes. Shown is an example in which the Nalb-Sal treatment induced greater
activation (i.e., caudate), and an example in which the Nalb-Nalox treatment induced greater activation (i.e., amygdala).
doi:10.1371/journal.pone.0050169.g002
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onset of the ramp can be variable depending on local pharma-
codynamics, we included additional singular value decomposition
regressors to enable unbiased estimation [16] of the infusion
amplitude. Further, linear drift and subject specific average time
courses extracted from the WM and CSF were included as
covariates of no interest in the GLM. The statistical outputs from
Table 1. Nalb-Sal-induced changes in BOLD activity.
Coordinates
(mm) Volume
Brain Region Lat. Z-stat x y Z cm
3
Increased Response
Cortical
Occipital
Rolandic Operculum R 3.48 44 0 14 1.064
Rolandic Operculum L 3.07 244 212 18 1.168
Rolandic Operculum R 3.78 54 226 20 4.536
Calcarine R 3.42 30 252 10 0.832
Calcarine R 3.72 30 258 10 1.048
Middle R 4.07 46 276 24 2.66
Middle R 4.06 42 282 24 2.552
Temporal
Pole Superior L 2.86 250 18 216 0.432
Inferior R 2.84 50 2 236 0.976
Inferior L 4.23 252 26 234 1.16
Superior R 3.84 54 238 14 1.08
Superior R 3.30 50 240 12 1.216
Inferior L 3.18 246 248 218 0.784
Inferior L 3.35 250 250 216 0.288
Fusiform L 4.12 246 254 218 0.996
Insula
Insula Anterior L 3.38 238 8 8 1.808
Insula Anterior R 2.97 38 4 12 2.272
Insula Anterior L 3.75 242 2 10 1.504
Insula Anterior L 3.07 236 2 12 0.224
Insula Posterior L 2.80 232 22 12 0.576
Insula Posterior R 3.55 34 24 16 0.672
Insula Posterior L 2.89 236 212 18 0.808
Sub-Cortical
Thalamus L 3.15 22 214 2 1.008
Thalamus (pulvinar) R 4.56 10 230 8 0.688
Thalamus (pulvinar) L 3.86 210 230 10 0.656
Caudate L 2.99 218 218 24 0.512
Hippocampus R 3.66 32 230 210 1.672
Hippocampus L 3.45 232 232 212 2.152
Hippocampus R 4.04 30 234 28 0.728
Hippocampus L 3.81 214 236 2 0.864
Hippocampus L 2.88 234 236 28 0.576
Hippocampus L 3.61 222 238 0 1.136
Hippocampus L 3.72 228 238 24 1.232
Brainstem/Cerebellum
Pons L 3.20 26 218 234 0.504
Pons B 2.61 0 222 240 0.6
Pons L 2.57 26 222 238 0.312
Pons B 2.80 0 224 232 0.376
msn L 4.31 220 232 236 5.128
Cerebellum 8 L 3.48 220 238 248 0.4
Crus 4 5 L 2.93 216 238 230 0.288
Cerebellum 10 L 3.40 220 240 244 0.552
Table 1. Cont.
Coordinates
(mm) Volume
Brain Region Lat. Z-stat x y Z cm
3
Cerebellum 9 R 3.48 36 242 248 0.6
Cerebellum 4 5 R 2.84 16 242 228 0.632
Cerebellum Crus1 R 3.51 20 246 240 1.28
Cerebellum 9 R 4.07 40 248 242 0.928
Cerebellum 9 L 3.58 22 248 244 0.352
Cerebellum 7b R 3.58 4 258 246 1.624
Vermis 9 R 2.80 24 252 230 0.496
Vermis 9 L 2.83 222 252 232 2.112
Cerebellum 8 L 3.88 230 252 242 1.664
Cerebellum 8 R 2.86 36 252 246 0.568
Cerebellum 8 L 3.86 230 252 254 0.888
Cerebellum Crus1 R 3.27 36 254 234 0.536
Cerebellum 8 L 3.84 216 256 248 0.56
Cerebellum 4 5 L 3.05 26 256 212 0.536
Cerebellum 8 L 3.19 214 260 258 0.872
Cerebellum 8 L 3.93 224 262 250 2.328
Cerebellum Crus1 R 3.46 24 264 234 1.616
Cerebellum Crus1 L 4.13 244 274 230 2.688
Cerebellum I–IV L 2.91 214 244 226 0.48
Decreased Response
Cortical
Frontal
Middle R 22.46 14 62 22 4.296
Inferior Orbital R 23.48 34 16 224 0.68
Parietal
Postcentral (S1) R 23.63 14 240 78 0.936
Postcentral (S1) R 23.34 20 240 76 1.312
Precuneus B 22.86 0 248 44 1.464
Temporal
Pole Superior R 23.55 38 12 224 0.664
Pole Superior L 23.44 238 10 226 2.168
Cerebellum
Cerebellum 3 L 23.12 214 232 224 1.032
Cerebellum 4 5 R 22.87 10 240 212 2.24
Group averages for significant Nalb-Sal-induced changes in BOLD activity.
General brain regions, given in the left column, may contain several significantly
activated/deactivated regions, each listed with its MNI-152 coordinates. See
Fig. 3 (‘‘Nalb-Sal’’) for maps depicting the data in this table. ‘‘Lat.’’ indicates the
brain laterality (i.e., R=right side, L=left side). Z-stat is given for each region.
Coordinates: x=mm right (positive values) or left (negative values); y=mm
anterior (positive values) or posterior (negative values); and z=mm superior
(positive values) or inferior (negative values). Volume is the volume of the
region showing significant BOLD activation or deactivation.
doi:10.1371/journal.pone.0050169.t001
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using precomputed affine transformations.
Group level. For all group-level phMRI analyses, single
subject GLM statistics for the amplitude of the ‘‘infusion EV’’ were
entered into a paired mixed-effects group-level GLM analysis
using a paired t-test design with FLAME [17]. The contrasts of
interest were Sal-Nalb.Nalox-Nalb and Sal-Nalb,Nalox-Nalb.
Functional connectivity analysis
Differences in functional connectivity (Fc) between the Nalox-
Nalb and Sal-Nalb conditions for specific brain structures were
calculated. Only phMRI data from the last 5 min were analyzed
for Fc because the drug effects were in a steady state during this
time. A seed-based analysis was performed as described below:
Region of interest selection. Biologically relevant regions of
interest (ROIs) were defined in the standard space MNI 152
template and subsequently linearly transformed into the subject-
specific fMRI space for functional connectivity analysis.
ROIs that showed significant differences in Fc were selected on
the basis of evidence for such changes in observed phMRI infusion
responses between Sal-Nalb and Nalox-Nalb treatments.
Single subject Fc analysis. Functional connectivity analysis
was performed utilizing a partial correlation coefficient approach
between all brain voxels and the seed time course given the
average WM, average CSF, and the linear drift as nuisance
covariates. The seed time course was defined as the averaged time
course of all the voxels within an ROI. We used partial correlation
because it was recently shown to have good sensitivity in detecting
network connections [18].
Group-level Fc analysis. The raw partial correlation coef-
ficient maps from single subject analysis were variance-stabilized
using a Fisher z-transform and transformed to the MNI 152 space
using precomputed affine transformations. The resulting
z-transformed maps were entered into a random effects group-
level GLM analysis using a paired t-test design. As in the case of
infusion analysis, the contrasts of interest were Sal-Nalb.Nalox-
Nalb and Nalox-Nalb-.Sal-Nalb.
Statistical inference and thresholding. The z-statistic
maps for each contrast in the infusion analyses as well as the
functional connectivity analyses were subjected to alternative
hypothesis testing using Gaussian mixture modeling [19]. In each
case, the mixture model was spatially regularized using a Markov
random field (MRF) that was a soft-max prior on the class labels
[20]. This prior encourages spatially neighboring voxels to have
similar labels. The mixture model parameters as well as the MRF
parameter were adaptively estimated from the data using iterated
conditional modes (ICM) [20]. The posterior probability maps
(PPMs) giving the ‘‘activation’’ probability of a voxel conditional
on the estimated labels in its neighborhood and the observed data
were created and thresholded at PPM.0.5 to detect ‘‘activation’’.
PhMRI comparisons with morphine and naloxone
In order to infer biological relevance from the differences in the
patterns of brain activation by Sal-Nalb and Nalox-Nalb, we
compared the results of the current study with those of previous
studies of morphine [8] and naloxone [9], which employed the
same infusion protocol as that for the actual Nalbuphine
administration.
Results
Psychophysical ratings and physiological measures
There were no significant differences between the two groups in
euphoria-dysphoria scores, respiratory rate, end tidal CO2,o r
heart rate (data not shown).
phMRI infusion responses
PhMRI BOLD responses. Sal-Nalb and Nalox-Nalb pro-
duced significant changes in activity in many brain regions.
Representative examples of the time courses of changes in
activation are shown in Fig. 2. In caudate and anterior insula
Sal-Nalb induced greater signal changes than did Nalb-Nalox; in
contrast, the effects were opposite in the amygdala and the middle
cingulate cortex (MCC). Except for the MCC, these changes
commenced soon after nalbuphine infusion started. These signal
changes exemplify the data used to derive the statistically
significant signal changes for regional activation shown in
Tables 1, 2, and 3 and mapped in Fig. 3.
Effects of Sal-Nalb on brain activation. Increased BOLD
responses were observed in 60 brain regions including, the
occipital cortex, temporal cortex (mostly inferior), anterior and
posterior insula, thalamus, caudate, hippocampus, pons, and
Table 2. Nalb-Nalox-induced changes in BOLD activity.
Coordinates
(mm) Volume
Brain Region Lat. Z-stat x Y z cm
3
Increased Response
Cortical
Temporal
Lingual L 3.41 226 248 28 5.048
Insula
Insula Anterior L 3.78 236 18 28 1.36
Insula Anterior L 4.42 238 10 212 3.216
Insula Anterior R 3.22 42 8 26 2.072
Insula Anterior R 3.72 36 4 26 6.904
Insula Anterior R 3.76 38 0 26 0.96
Sub-Cortical
Putamen R 3.34 30 28 2 3.448
Brainstem/Cerebellum
spV L 4.42 22 244 258 9.96
Cerebellum 4 5 R 3.81 14 250 220 1.64
Vermis 4 5 R 4.65 6 254 218 2.48
Vermis 6 B 3.51 0 262 220 1.208
Cerebellum 8 L 4.39 218 260 252 4.632
Cerebellum 9 L 3.82 218 244 260 10.288
Cerebellum 10 L 3.14 214 240 244 1.064
Decreased Response
Cortical
Frontal
Superior R 23.18 14 52 0 0.592
Inferior Orbital L 22.80 228 24 222 1.832
Occipital
Superior L 22.32 28 296 6 0.624
Group averages for significant Nalb-Nalox-induced changes in BOLD activity.
See caption for Table 1 for explanation of the columns. See Fig. 3 (‘‘Nalb-Nalox’’)
for maps depicting the data in this table. Note that no subcortical, brainstem, or
cerebellar regions showed significantly decreased activity.
doi:10.1371/journal.pone.0050169.t002
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including the middle frontal cortex, inferior orbitofrontal cortex,
post central parietal cortex, superior temporal pole, and cerebel-
lum (Table 1, see Fig. 3 for maps). We interpret these changes
to reflect de novo effects of nalbuphine.
Effects of Nalox-Nalb on brain activation. Nalox-Nalb
produced a very different pattern of changes in activity; fewer
regions showed increased activity (n=14) and also fewer regions
showed decreased activity (n=3) compared to Sal-Nalb. Regions
with increased activity included the lingual cortex, the anterior
insula but not the posterior insula, and the cerebellum. Decreased
responses were only observed in the inferior orbital region
(Table 2, Fig. 3). Thus, based on infusion activation patterns,
large differences were apparent between the Sal-Nalb and Nalox-
Nalb sessions.
Differences in brain activation. Low-dose naloxone signif-
icantly blocked nalbuphine activation (i.e., Sal-Nalb.Nalox-Nalb)
in superior medial and middle frontal cortex, postcentral parietal
cortex (lateral aspect), occipital cortex (rolandic operculum),
caudate, pons (trigeminal main sensory nucleus) and cerebellum
(Table 3, Fig. 3). Addition of naloxone also induced activation of
some areas significantly more than nalbuphine alone (i.e., Nalox-
Nalb.Sal-Nalb); these included the superior and inferior orbital
cortex (rostral), postcentral parietal cortex (superior aspect),
occipital cortex (cuneus), temporal cortex (middle and superior
poles), amygdala, putamen, pulvinar, and areas in the cerebellum.
Functional connectivity
Of the regions tested (e.g., thalamus, anterior insula, posterior
insula, anterior cingulate, posterior cingulate, and caudate), only
caudate was found to demonstrate significant Fc. Nalbuphine
induced functional connectivity of the caudate with the following
cortical areas: superior frontal, superior medial frontal, and middle
frontal, middle orbitofrontal, inferior operculum, precentral
frontal, superior and inferior parietal, calcarine and middle
occipital, superior temporal and fusiform, middle cingulate, and
anterior insula (Table 4, Fig. 4). Naloxone eliminated this
connectivity between the caudate and all of these areas.
Discussion
In this study we investigated the effect of nalbuphine on brain
circuitry implicated in analgesia and pain. For this analysis we
used phMRI to identify changes in BOLD activity following
Table 3. Contrast analyses for Nalb-Sal vs Nalb-Nalox.
Coordinates
(mm) Volume
Brain Region Lat. Z-stat x Y z cm
3
Nalb-Sal,Nalb-Nalox
Cortical
Frontal
Superior Orbital R 3.83 16 64 0 0.808
Superior R 3.82 12 62 0 0.6
Superior R 3.40 12 60 4 1.928
Inferior Orbital R 3.30 44 32 28 6.568
Parietal
Postcentral R 3.46 24 242 72 19.36
Occipital
Cuneus R 3.50 18 276 40 1.72
Temporal
Pole Middle R 3.54 36 16 238 1.512
Pole Superior L 4.13 242 12 226 1.424
Pole Superior L 3.19 234 8 226 0.664
Superior Temporal Lobe L 3.78 242 22 220 1.224
Cingulum
Middle R 3.03 2 212 42 4.456
Insula
Insula Anterior R 3.35 26 16 220 5.52
Sub-Cortical
Amygdala L 3.29 230 2 220 1.448
Putamen R 3.72 28 210 4 4.408
Thalamus (pulvinar) R 3.35 18 226 4 1.088
Brainstem/Cerebellum
Cerebellum Crus2 L 3.28 226 278 240 2.08
Cerebellum Crus2 R 3.72 4 280 236 1.408
Cerebellum Crus2 R 3.24 18 282 246 2.008
Nalb-Sal.Nalb-Nalox
Cortical
Frontal
Superior Medial L 4.17 210 32 38 1.328
Superior Medial L 3.12 26 32 34 0.912
Superior Medial L 3.95 28 28 36 1.664
Middle L 4.06 230 4 50 9.712
Parietal
Postcentral R 2.98 58 220 38 0.872
Occipital
Rolandic Operculum R 3.74 42 0 16 1.216
Rolandic Operculum R 3.77 42 24 16 0.424
Sub-Cortical
Caudate L 4.15 218 26 24 1.448
Caudate L 3.77 218 216 24 0.944
Caudate R 24.45 14 18 16 4.344
Brainstem/Cerebellum
CN V main sensory n. R 4.02 2 228 238 1.056
CN V main sensory n. L 4.07 26 228 236 2.408
Table 3. Cont.
Coordinates
(mm) Volume
Brain Region Lat. Z-stat x Y z cm
3
Pons R 3.51 6 226 234 0.616
Cerebellum Crus2 R 3.17 38 278 242 3.592
Regions in which there were significant differences in activity induced by the
two treatments without regard to the absolute value of the BOLD signal in
these regions. Thus, a region may show a significant contrast even in the
absence of significant activation or deactivation by either of the treatments.
Regions where Nalb-Nalox induced significantly greater activity than Nalb-Sal
are shown in the top section of the table; regions where Nalb-Sal induced
significantly greater activity than Nalb-Nalox are shown in the lower section of
the table. See caption for Table 1 for explanation of the columns. See Fig. 3
(‘‘Contrast Maps: Nalb-Sal vs Nalb-Nalox’’) for maps depicting the data in this
table.
doi:10.1371/journal.pone.0050169.t003
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Nalbuphine preceeded by saline (i.e., Sal-Nalb) administration
significantly increased activity in 60 discreet brain regions and
decreased it in 9 (Table 1); nalbuphine pretreated with naloxone
(i.e., Nalox-Nalb) significantly increased activity in only 14 regions
and decreased it in only 3 (Table 2). Given that nalbuphine is an
opioid agonist and naloxone an opioid antagonist, these results
should perhaps not be surprising; naloxone blocked many actions
of nalbuphine. These results might help explain nalbuphine’s pain-
facilitating effect when administered alone and its analgesic effect
when pretreated with naloxone. Importantly, although pain
measures are not presented in the present study, the relevance of
the various identified brain regions to analgesia/algesia has been
well established in previous studies (see Table 5).
Actions of Nalbuphine (Nalb-Sal)
Because nalbuphine is widely employed as an analgesic, but also
produces a marked pain-facilitation in males, its phMRI brain
signature might be expected to show characteristics typical of both
analgesia and pain, and this is indeed the case. Nalbuphine acted
at sites associated with the production of analgesia in that it
attenuated activity in some brain regions in which activity was also
attenuated by morphine (see Table 5; data from our prior study
[8]). However, it also activated many areas that are activated by
noxious stimulation, areas that were not activated by either
morphine or nalbuphine pretreatment with naloxone. Like
morphine, nalbuphine attenuated activity in the inferior orbital
cortex, but, like noxious stimulation, it increased activity in several
regions in the temporal cortex, insula, thalamus (including
pulvinar), caudate, and pons. In contrast to noxious stimulation,
nalbuphine decreased activity in the primary somatosensory cortex
(S1) and precuneous regions. In addition, nalbuphine induced
functional connectivity of the caudate and multiple regions in the
frontal, occipital, temporal, insular, middle cingulate cortices, the
putamen, and many areas in the cerebellum.
Actions of Nalbuphine in the Presence of Naloxone
(Nalb-Nalox)
Fewer brain regions were activated when nalbuphine was
administered with naloxone, down from 60 to 14, and also fewer
regions were deactivated, down from 9 to 3 (Table 5). Given that
naloxone abolishes nalbuphine-induced pain-facilitation and
induces significantly enhanced analgesia [4], these results suggest
that naloxone blockade affects activity in areas that mediate pain
facilitation. Consistent with this suggestion, regions in which
naloxone blocked activity included pulvinar, which has been
associated with increased activation in central sensitization [21],
pons, which has been implicated in remifentanil withdrawal
hyperalgesia [22], posterior insula, which is associated with pain-
exclusive activations [23], and many areas in the cerebellum,
which may have a role in pain processing [24]. Connectivity
analysis showed that naloxone reduced nalbuphine-induced
functional connectivity of caudate with all regions; that is, there
was no significant connectivity in the presence of naloxone.
Figure 3. BOLD phMRI activation maps. Top: BOLD activation maps for Nalb-Sal (see Table 1); middle: BOLD activation maps for Nalb-Nalox
infusions (see Table 2). Bottom: Contrast maps for Nalb-Sal.Nalb-Nalox and Nalb-Nalox.Nalb-Sal (see Table 3).
doi:10.1371/journal.pone.0050169.g003
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(putamen, cingulate, temporal lobe, and cerebellum) showed
significantly greater BOLD activation (Tables 3, 5). Increased
activation of putamen was also observed with morphine [8],
consistent with a role of this region in analgesia [25]. These results
suggest that nalbuphine-induced activation of caudate (perhaps by
Table 4. Connectivity analysis for the caudate.
Coordinates
(mm) Volume
Brain Region Lat. Zstat X Y z cm
3
Nalb-Sal.Nalb-Nalox
Cortical
Frontal
Superior Medial L 2.82 210 24 38 0.592
Superior L 3.27 218 10 54 0.496
Middle L 2.82 228 40 28 2.536
Middle Orbital R 3.51 42 52 8 0.584
Middle Orbital R 3.16 30 36 38 1.744
Middle Orbital R 2.73 30 32 32 0.608
Middle Orbital R 3.28 30 24 38 0.68
Inferior Orbital R 2.65 50 24 24 0.696
Inferior Orbital R 2.70 46 18 214 0.528
Inferior Orbital L 3.36 246 16 210 0.976
Inferior Triangular R 3.26 48 40 4 1.000
Inferior Operculum R 3.05 50 8 16 0.608
Inferior Operculum R 2.67 54 8 8 0.496
Inferior Operculum L 2.85 246 8 4 0.48
Inferior Operculum R 2.96 48 6 26 0.624
Inferior Operculum R 2.88 42 4 26 0.312
Precentral R 3.37 44 6 32 1.376
Precentral R 2.73 54 6 32 0.464
Precentral L 3.68 234 4 40 2.696
Parietal
SupraMarginal R 2.93 60 224 32 1.336
SupraMarginal R 4.33 54 230 40 5.24
Postcentral R 3.42 28 236 40 0.472
Inferior L 3.11 256 236 38 1.848
Inferior R 2.87 44 238 48 0.992
SupraMarginal R 2.93 42 242 40 0.784
Superior R 3.13 46 244 56 1.608
Inferior L 3.35 244 244 44 1.696
Inferior L 2.84 246 246 52 1.168
Inferior R 2.79 42 248 46 0.424
Angular R 2.65 30 252 44 2.728
Superior R 3.26 20 262 64 2.8
Superior L 2.86 230 264 58 1.016
Occipital
Middle L 2.94 226 266 30 0.504
Middle R 3.23 36 270 30 0.704
Middle L 4.07 230 274 26 2.144
Middle R 2.65 32 276 22 1.536
Middle R 2.79 34 278 34 0.56
Calcarine R 3.03 22 280 8 0.304
Middle L 3.46 232 282 32 1.064
Temporal
Superior L 2.99 244 2 28 0.328
Fusiform R 3.41 32 22 236 0.456
Table 4. Cont.
Coordinates
(mm) Volume
Brain Region Lat. Zstat X Y z cm
3
Fusiform R 3.25 28 232 224 0.36
Cingulum
Middle R 2.77 12 24 36 0.416
Insula
Anterior R 2.97 40 20 24 0.576
Anterior L 3.54 238 16 4 2.272
Anterior R 3.57 44 14 2 2.144
Anterior R 3.32 48 14 26 0.888
Sub-Cortical
Putamen R 2.91 30 16 6 2.04
Cerebellum
Cerebellum 4 5 L 2.8902 222 226 228 0.624
Cerebellum 4 5 R 2.9845 20 234 222 0.392
Cerebellum 4 5 R 2.8301 20 238 222 0.24
Cerebellum 4 5 L 3.3849 218 242 224 1.472
Cerebellum 4 5 R 3.0935 22 246 220 2.176
Cerebellum 4 5 L 2.9436 218 250 226 1.032
Cerebellum 6 R 3.6119 32 236 232 1.376
Cerebellum 6 L 2.8626 228 242 230 0.656
Cerebellum 6 L 2.7682 232 242 230 0.376
Cerebellum 6 L 3.3063 242 244 230 0.936
Cerebellum 6 L 2.8028 226 250 228 0.784
Cerebellum 6 R 2.6501 24 260 226 0.96
Cerebellum 6 L 2.9134 26 262 210 1.32
Cerebellum 6 R 2.7873 38 264 226 0.968
Cerebellum 6 L 2.8994 212 264 218 2.32
Cerebellum 8 L 3.2813 216 266 242 1.056
Cerebellum 6 R 2.8994 26 266 224 0.552
Cerebellum 6 R 3.073 16 270 220 2.36
Cerebellum 6 R 2.6594 34 272 224 0.248
Cerebellum 6 R 3.5358 24 274 218 1.048
Cerebellum Crus1 L 2.9171 242 250 232 0.28
Cerebellum Crus1 R 2.7828 54 254 234 1.08
Cerebellum Crus1 L 3.4277 252 256 232 1.376
Cerebellum Crus1 R 2.6522 52 260 228 1.168
Cerebellum Crus1 L 2.9529 234 268 226 1
Cerebellum Crus2 L 2.9329 238 258 244 1.12
Cerebellum 7b L 2.6767 216 278 244 0.472
Regions demonstrating significant functional connectivity to the caudate. Note
that only Nalb-Sal showed significant connectivity. See caption for Table 1 for
explanation of the columns. See Fig. 4 for maps depicting the data in this table.
doi:10.1371/journal.pone.0050169.t004
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connectivity with other regions, and, although the receptor(s)
involved is not known, blockade of this connectivity by naloxone
abolishes this pronociceptive effect.
Drug Modulation of Interoception
The insula is postulated to be involved in interoception or a
state of subjective feeling, defined as sensitivity to stimuli originating
inside of the body [26]. The region, specifically the mid/posterior
insula is connected with the posterior middle cingulate cortex
(pMCC) that may ‘‘integrate interoceptive information with
emotional salience to form a subjective representation of the
body’’ [27]. Such ongoing subclinical processing may be altered by
naloxone-nalbuphine vs. saline-nalbuphine effects. In essence,
changes akin to those surmised in drug addiction may be present,
albeit acutely [28]. A potential mechanism of the changes
observed here (i.e., naloxone-induced inhibition of the insula
cortex) may relate to naloxone effects on opioid receptors in the
insula. The insula has high concentrations of opioid receptors [29]
and naloxone may act to block an opioid-induced effect – i.e., the
nalbuphine effects on the posterior insula. In support of this,
naloxone infusion in healthy subjects, as measured by arterial spin
labeling showed increases in insula blood flow following fentanyl,
but not naloxone [30]. In a similar manner, the effect of naloxone
may be to decrease effective action of nalbuphine.
Time course of effects
In males nalbuphine by itself induces early onset analgesia that
descends into anti-analgesia between 40 and 90 minutes after
administration, depending on dose [3]. For the 5 mg dose of
nalbuphine, the approximate dose used in the current study, the
duration of analgesia is shorter—about 30 minutes—and the
appearance of anti-analgesia is earlier than for higher doses [3].
Thus, since the plasma half-life of naloxone is about an hour [31],
the timing of the effects of naloxone observed in the present study
are consistent with our clinical observations. Of note, it is likely
that nalbuphine alone activates both analgesia and algesia
mechanisms at the same time and that addition of naloxone
eliminates that effect on the algesic circuitry.
Brain Generated Pain Enhancement
An important implication of these findings is that the brain can
generate de novo pain enhancement elicited by the action of a drug
such as nalbuphine. Aside from the clinical data arising from
lesions of the nervous system (e.g., thalamic or brainstem stroke),
few studies have investigated pain facilitation in the brain.
Derbyshire and colleagues [32] showed that hypnotically-induced
pain is accompanied by activation of classic pain regions, including
anterior cingulate cortex (ACC), insula, and prefrontal cortex.
Kong and colleagues [33] found that an expectation/conditioning
manipulation model can produce a nocebo effect (expectation-
induced pain enhancement, opposite of the placebo effect)
correlated with activation of the medial pain system. Remifentanil
offset or withdrawal is associated with acute opioid withdrawal
hyperalgesia with increased activation in the mesencephalic
pontine reticular formation [22]. We previously reported that
naloxone alone, in contrast to its effect on nalbuphine-induced
enhancement in pain circuits in the present study, increased brain
activation induced by noxious thermal stimulation [9]. Thus, the
brain appears to contain circuitry necessary for pain facilitation,a
phenomenon distinct from pain induction or transmission, as
nalbuphine alone does not induce pain.
Direct interventions in pain pathways can modulate nociceptive
responses mediated by descending pathways. These include both
non-opioid and opioid-based manipulations. Calejesan and
colleagues [34] showed that either electrical stimulation or
microinjection of a metabotropic glutamate receptor agonist into
ACC facilitated the nociceptive tail-flick reflex (i.e., enhanced
nociception), and these effects were mediated through the rostral
ventral medulla (RVM). In contrast, electrical stimulation of the
ACC reduces responses of dorsal horn neurons to noxious
mechanical stimuli, suggesting an analgesic effect [35]. Although
the findings of these studies disagree in terms of polarity, they
agree that manipulation in the ACC, an important region in pain
Figure 4. Functional Connectivity Maps. Caudate functional connectivity induced by Nalb-Sal that was blocked by naloxone (see Table 4). There
was no functional significant connectivity induced by the Nalb-Nalox treatment.
doi:10.1371/journal.pone.0050169.g004
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Region Subregion Pain Nalb-Sal Nalb-Nalox Contrasts
Activ. Connect. Activ. Morph Nalox NN.NS NS.NN
Frontal Superior + 1 212
Superior medial + 13
Middle 211 1
Superior orbital 1
Middle orbital 4
Inferior orbital + 213 21 22 + 1
Inferior triangular 1
Inferior operculum 5
Precentral 3
Occipital Rolandic operculum +32
Calcarine +21
Middle +26
Superior 21
Cuneus 1
Temporal Superior pole ++ 1 22 + 2
Middle pole ++ 1
Superior ++ 21
Inferior ++ 4
Fusiform ++ 12
Lingual +1
Superior lobe 1
Parietal Postcentral (S1, superior) + 221 1
Postcentral (S1, lateral) + 1
Precuneous + 21
Supramarginal 3
Superior 3
Inferior 5
Angular 1
Insula Anterior ++ 44 +51
Posterior ++ 3 +
Cingulate Middle + 1 + 1
Sub-cortical Thalamus ++ 1 22
Pulvinar +21
Caudate ++ 13
Putamen 1 +1 +21
Nucleus accumbens - +2
Amygdala 1
Substantia nigra +1
Hypothalmus +1
Sublenticular extension +1
Hippocampus ++ 7 +2 +
Pallidum +
PAG ++
Pons ++ 41
spV 1
Main sensory n. CN V +12
Cerebellum ++ 22 222 7+63 1
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spinal cord. Moreover, there is evidence of connectivity between
the ACC and the descending pain modulation system. Neural
afferent projections from ACC to the periaqueductal gray (PAG)
have been reported [36,37], and functional connectivity based on
fMRI data from 100 subjects has been reported between ACC,
PAG, and RVM [38]. Interestingly, this study, which included
equal numbers of males and females, also found sexually
dimorphic functional connectivity at the mid-cingulate cortex.
Others have reported sex differences in brain processing in a
number of regions, including the perigenual cingulate cortex, in a
study of equal pain experience induced by laser stimulation [39].
Whether these differences contribute to the sex differences in
analgesic efficacy observed in our clinical studies [1,2,3,4] remains
to be investigated.
Limitations
A few caveats of this study need to be considered. (i) Although
12 subjects per cohort is a reasonable number for phMRI studies
[40], smaller effects are probably not statistically robust enough to
be detected. (ii) We did not observe significant differences in
functional connectivity, the results probably were affected by the
use of whole anatomical areas, rather than specific areas associated
with significant differences. In order to use ROIs defined by
statistical differences a different cohort of subjects would have been
needed at it is not statistically correct to use the same cohorts to
derive an ROI for secondary functional connectivity analysis. (iii)
Prolonged effects on brain systems by low single dose naloxone is
futher supported by prolonged (for hours) opioid receptor binding
(as measured by [
11C]-carfentanil displacement by naltrexone)
[41]. In addition in our prior study of naloxone infusions in
healthy men (albeit at higher doses), effects on brain system
activation was observed within 10 minutes following the infusion
and later (i.e., .20 min following the infusion) subjective measures
of pain intensity and unpleasantness revealed significant differ-
ences even though no significant effects on BOLD were observed
approximately 10 minutes after the initial infusion [9]. (iv) We did
not perform a dose-response/multiple dose study across healthy
subjects and patients that may provide insights into differences in
response between the two groups. Such phMRI studies would help
differentiate the effects of clinical pain on the phMRI signal. (v)
Future studies evaluating effects in healthy and clinical groups of
men and women would be needed to further dissect the
pharmacological and psychometric differences across gender.
Conclusions
This study provides support for the use of phMRI in our
understanding of the mechanism of action of CNS-acting
analgesics and the development of more selectively targeted
agents. The brain activity signature of nalbuphine demonstrates
characteristics typical of both noxious stimulation and the opioid
analgesic morphine, thus providing a neural basis for its
paradoxical ability to produce both analgesia and pain-facilitation.
Naloxone selectively blocks the actions of nalbuphine in brain
regions associated with pain, leaving the analgesic-like actions
intact. Given these findings, and that nalbuphine alone does not
produce pain, it is possible that nalbuphine interacts with a pain
salience system, which can modulate perceived pain intensity
relative to the nature of the initial insult.
Although nalbuphine is the k-agonist antagonist we have
studied most extensively [2,3,4], we have shown that the other two
clinical agents in this class, pentazocine and butorphanol, behave
similarly [1,2], strongly implying similar mechanisms of action of
this class of opioid drugs. All three drugs in this class are known to
act at multiple receptors; therefore, it will be important to identify
the specific receptors mediating pain enhancement compared to
those that mediate analgesia, in order to develop more efficacious
analgesic treatments.
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Table 5. Cont.
Region Subregion Pain Nalb-Sal Nalb-Nalox Contrasts
Activ. Connect. Activ. Morph Nalox NN.NS NS.NN
Totals +60 297 4 +14 23 +9 24
This table summarizes the data from the present study and three earlier studies in healthy male volunteers. Plus signs (+) indicate brain regions showing significant
activation; minus signs (2) indicate brain regions showing significant deactivation. Numbers indicate count of discreet brain sites within each named subregion.
Columns:
‘‘Pain’’ Brain regions showing statistically significant BOLD signal changes in our study of noxious stimulation [42]. Note that the count of discrete brain sites within each
named subregion is not shown here.
‘‘Nalb-Sal.’’ Consists of two subcolumns ‘‘Activ.’’ and ‘‘Connect.’’
‘‘Activ.’’ Brain regions showing statistically significant BOLD signal changes in response to saline followed by nalbuphine (Table 1).
‘‘Connect.’’ Brain regions showing statistically significant functional connectivity with respect to caudate (Table 4). Numbers indicate count of discreet brain sites within
each named subregion showing functional connectivity. Note that this only occurred in the Nalb-Sal group; no significant connectivity was observed in the Nalb-Nalox
group.
‘‘Nalb-Nalox’’ Brain regions showing statistically significant BOLD signal changes in response to naloxone followed by nalbuphine (Table 2).
‘‘Morph’’ Brain regions showing statistically significant BOLD signal changes in our study of morphine [8].
‘‘Nalox’’ Brain regions showing statistically significant BOLD signal changes in our study of naloxone (Borras et al., 2004). Note that the count of discrete brain sites
within each named subregion is not shown here.
‘‘Contrasts’’ Consists of two subcolumns ‘‘NN.NS’’ and ‘‘NS.NN.’’ The numbers indicate the count of discreet sites demonstrating significant differences in BOLD
activation/deactivation between the two treatments (Table 3); therefore, individual sites in may or may not be found in Tables 1 or 2.
‘‘NN.NS’’ Regions where naloxone followed by nalbuphine showed significantly greater activation than saline followed by nalbuphine.
‘‘NS.NN’’ Regions where saline followed by nalbuphine showed significantly greater activation than naloxone followed by nalbuphine.
All studies represented in the table were performed using the 3T Siemens scanner, and the studies for morphine and naloxone used the same infusion protocol as the
current study.
doi:10.1371/journal.pone.0050169.t005
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